Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Gross Margin (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Gross Margin for 16 consecutive years, with 7.89% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 3935.0% year-over-year to 7.89%, compared with a TTM value of 10.94% through Sep 2025, up 2340.0%, and an annual FY2024 reading of 43.84%, down 3983.0% over the prior year.
  • Gross Margin was 7.89% for Q3 2025 at China Pharma Holdings, up from 8.48% in the prior quarter.
  • Across five years, Gross Margin topped out at 11.56% in Q1 2021 and bottomed at 109.78% in Q2 2024.
  • Average Gross Margin over 5 years is 13.79%, with a median of 10.56% recorded in 2022.
  • The sharpest move saw Gross Margin plummeted -9642bps in 2024, then skyrocketed 10130bps in 2025.
  • Year by year, Gross Margin stood at 10.45% in 2021, then tumbled by -86bps to 1.46% in 2022, then tumbled by -352bps to 3.68% in 2023, then tumbled by -285bps to 14.16% in 2024, then soared by 44bps to 7.89% in 2025.
  • Business Quant data shows Gross Margin for CPHI at 7.89% in Q3 2025, 8.48% in Q2 2025, and 11.97% in Q1 2025.